Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 8 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Seagen Inc. currently has 12 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution of these matters involves 11 distinct examiners and is spread across 8 distinct art units. This high ratio of examiners and art units relative to the total number of pending actions suggests a diverse array of biological or pharmaceutical technologies being pursued. The busiest examiner for this portfolio is PUTTLITZ, KARL J, who is currently managing 2 pending office actions.
Because no single examiner holds more than 2 of the 12 total actions, the portfolio's success is highly dependent on the individual tendencies of 11 different examiners. Navigating 8 distinct art units requires a versatile approach to prosecution, as each unit may have different internal guidelines or interpretations of patentability within the Biotechnology & Pharmaceuticals field. Practitioners must manage a complex array of deadlines and examiner interactions, with only minimal overlap in examiner assignments. This broad distribution across 11 examiners and 8 art units indicates that the 12 pending office actions cover a wide spectrum of the company's research and development efforts. The strategy for Seagen Inc. must therefore be highly individualized for each case while maintaining overall consistency in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (17%) |
| §102 only | 1 (8%) |
| Double-patenting only | 2 (17%) |
| Double-patenting + other | 4 (33%) |
| Multi-statute (no §101) | 3 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PUTTLITZ, KARL J | 2 | 69.2% | +18.5% |
| PETRASH, HILARY ANN | 1 | 65.6% | +50.2% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.4% |
| SHAMEEM, GOLAM M | 1 | 86.7% | +15.9% |
| BENAVIDES, JENNIFER ANN | 1 | 50.8% | +47.3% |
| HAM, JIEUN | 1 | 45.5% | +0.0% |
| LU, CHENG | 1 | 53.8% | +64.6% |
| DUFFY, PATRICIA ANN | 1 | 52.9% | +33.9% |
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
| XIAO, YAN | 1 | 67.3% | +52.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18467633 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SHAMEEM, GOLAM M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | LU, CHENG | 46d |
| 18448863 | CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF | HAM, JIEUN | — |
| 18182203 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | DUFFY, PATRICIA ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17926206 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND AN OXALIPLATIN-BASED CHEMOTHERAPY | XIAO, YAN | 43d overdue |
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | LU, CHENG | 46d |
| 18682886 | METHODS FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | PETRASH, HILARY ANN | — |
| 18018504 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | ALLEN, MARIANNE P | — |
| 18467633 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SHAMEEM, GOLAM M | — |
| 18449591 | METHODS OF REDUCING SIDE EFFECTS OF ANTI-CD30 ANTIBODY DRUG CONJUGATE THERAPY | BENAVIDES, JENNIFER ANN | — |
| 18222313 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | PUTTLITZ, KARL J | — |
| 18182203 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | DUFFY, PATRICIA ANN | — |
| Art Unit | Apps |
|---|---|
| 1646 | 3 |
| 1642 | 3 |
| 1644 | 1 |
| 1647 | 1 |
| 1674 | 1 |
| 1675 | 1 |
| 1643 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682886 | METHODS FOR TREATING NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | PETRASH, HILARY ANN | 1644 | §103§112DP | Non-Final OA | — | Pending | Feb 09, 2024 |
| 18018504 | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | ALLEN, MARIANNE P | 1647 | §102§103§112DP | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18467633 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SHAMEEM, GOLAM M | 1674 | DP | Non-Final OA | — | Pending | Sep 14, 2023 |
| 18449591 | METHODS OF REDUCING SIDE EFFECTS OF ANTI-CD30 ANTIBODY DRUG CONJUGATE THERAPY | BENAVIDES, JENNIFER ANN | 1675 | §103 | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18448863 | CYTOTOXIC COMPOUNDS AND CONJUGATES THEREOF | HAM, JIEUN | 1643 | §103§112 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18222313 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | PUTTLITZ, KARL J | 1646 | §102 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18039473 | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | LU, CHENG | 1642 | §103§112Other | Non-Final OA | 46d | Pending | May 30, 2023 |
| 18182203 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | DUFFY, PATRICIA ANN | 1645 | §102§112 | Non-Final OA | — | Pending | Mar 10, 2023 |
| 18025349 | METHODS FOR TREATING CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | STONEBRAKER, ALYSSA RAE | 1642 | §102§103DP | Non-Final OA | — | Pending | Mar 08, 2023 |
| 17926206 | METHODS OF TREATING HER2 POSITIVE CANCER WITH TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND AN OXALIPLATIN-BASED CHEMOTHERAPY | XIAO, YAN | 1642 | §103 | Final Rejection | 43d overdue | Pending | Nov 18, 2022 |
| 17762867 | Combination Anti-CD30 ADC, Anti-PD-1 and Chemotherapeutic for Treatment of Hematopoietic Cancers | ALSOMAIRY, SARAH ABDOALATIF | 1646 | DP | Final Rejection | 72d overdue | Pending | Mar 23, 2022 |
| 17634026 | TREATMENT OF CANCERS WITH ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | PUTTLITZ, KARL J | 1646 | §103DP | Non-Final OA | — | Pending | Feb 09, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSeagen Inc. has 12 pending office actions as of October 2026, spread across 8 art units and 11 examiners.
Karl J Puttlitz has the most, with 2 of Seagen Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
